Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
109.45%
-
Total 13F principal
-
$245,979,899
-
Principal change
-
+$8,355,054
-
Total reported market value
-
$269,836,182
-
Number of holders
-
33
-
Value change
-
+$10,411,904
-
Number of buys
-
13
-
Number of sells
-
12
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q4 2021
As of 31 Dec 2021,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
33 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$245,979,899
in principal (par value) of the bond.
The largest 10 bondholders included
DeepCurrents Investment Group LLC, D. E. Shaw & Co., Inc., LAZARD ASSET MANAGEMENT LLC, UBS OCONNOR LLC, AVIVA PLC, CITIGROUP INC, Verition Fund Management LLC, CSS LLC/IL, ADVENT CAPITAL MANAGEMENT /DE/, and OAKTREE CAPITAL MANAGEMENT LP.
This page lists
33
institutional bondholders reporting positions
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.